Home Ingredients Flexigo™ (Devil's Claw Joint Health)
Joint Health

Flexigo™ (Devil's Claw Joint Health)

Harpagophytum procumbens
Evidence Level
Moderate
2 Clinical Trials
5 Documented Benefits
3/5 Evidence Score

Flexigo™ is a standardized Devil'S claw extract (Harpagophytum procumbens, also Harpagophytum zeyheri) from Southern Africa — developed by Nexira (France) as natural joint health solution. Distinguished by standardized harpagoside content up to 20% (HPLC method), 100% Devil's Claw (carrier-free), sustainable wild-harvest sourcing from Southern African partnerships, and EFSA pending claims for joint health. Used for joint comfort, mobility, and flexibility, particularly in active people and aging populations.

Studied Dose 1.8-3 g/day extract providing 50-100 mg harpagosides daily; varies by standardization
Active Compound Harpagosides (iridoid glycosides); typical standardization 1-30% harpagosides

Benefits

Joint Pain and Mobility (Clinical Evidence)

Multiple RCTs of Devil's Claw extracts (including Flexigo-grade) show pain reduction and improved mobility in osteoarthritis. systematic review confirmed efficacy. Effect comparable to non-pharmaceutical alternatives.

Supported by Trial 1, Trial 2

Inflammation Marker Reduction

Devil's Claw extracts modulate inflammatory pathways; reduce inflammation markers in some trials. Mechanism: harpagoside and other iridoid compounds inhibit COX-2, lipoxygenase, NF-κB pathway.

Supported by Trial 1, Trial 2

EFSA Pending Claims

Two pending EFSA claims for Harpagophytum procumbens: (1) 'Helps to maintain joint health'; (2) 'Helps to maintain flexible joints and good mobility'. Pending status; reflects substantial evidence base for joint applications.

Supported by Trial 1, Trial 2

Athletic Application

Useful for active people and athletes with joint stress — supports recovery and ongoing joint comfort with intense use. Adjunct to comprehensive joint care.

Supported by Trial 2, Trial 1

Carrier-Free 100% Active Ingredient

Flexigo™ is 100% Devil's Claw (no carrier); allows precise dosing and high active concentration. Distinguishes from products diluted with maltodextrin or other fillers.

Supported by Trial 1, Trial 2

Mechanism of action

1

Harpagoside Anti-Inflammatory Activity

Harpagoside (and harpagide, procumbide) are iridoid glycosides — primary actives. Inhibit COX-2, lipoxygenase pathway, NF-κB activation. Mechanism similar in direction to NSAIDs but weaker effect; better tolerability.

2

Cytokine Modulation

Reduces pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6); contributes to joint inflammation reduction.

3

Cartilage Protection (Theoretical)

Some animal evidence for chondroprotective effects — protection of cartilage from inflammatory degradation. Clinical translation incomplete.

4

Sustainable Wild-Harvest Sourcing

Devil's Claw grows wild in Southern Africa (Namibia, Botswana, South Africa); roots harvested sustainably with rotation systems. Nexira maintains long-term sustainable supply chain partnerships.

Clinical trials

1
Devil's Claw for Osteoarthritis

Evidence review of Devil's Claw clinical trials for arthritis pain.

Pooled across multiple osteoarthritis trials.

Significant evidence for pain reduction and mobility improvement vs placebo. Effect comparable to other natural anti-inflammatory approaches. Established Devil's Claw as evidence-based joint health intervention.

2
Devil's Claw vs NSAIDs — Comparative Trials

Studies comparing Devil's Claw extracts to NSAIDs for joint pain.

Osteoarthritis patients.

Devil's Claw less effective than NSAIDs but better tolerated; reasonable adjunct or alternative for those needing chronic joint support without NSAID GI/cardiovascular risks.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated.
GI distress (nausea, diarrhea) — most common.
Headache.
Theoretical bleeding risk at high doses (modest antiplatelet effects).
Allergic reactions rare.
Bitter taste of extract.

Important Drug interactions

Anticoagulants — theoretical bleeding risk; modest at typical doses; consult.
Diabetes medications — modest hypoglycemic effects; monitor.
Gastric ulcers / severe GERD — Devil's Claw may stimulate gastric acid; avoid with active ulcer disease.
Anti-arrhythmic medications — theoretical effects on cardiac function.
Pregnancy — uterotonic effects historically; avoid supplementation in pregnancy.
Lactation — limited safety data; avoid.

Featured in these supplement guides

Joint Pain→

More Joint Health Ingredients

Joint Health
Curcuwin Ultra+® (144× Bioavailable Curcumin — OmniActive)
Curcuwin Ultra+® is OmniActive's highly bioavailable curcumin — distinguished by 144× grea…
Joint Health
NEM® (Natural Eggshell Membrane — ESM Technologies)
NEM® is the branded standardized natural eggshell membrane developed by ESM Technologies (…
Joint Health
Undenatured Type II Collagen
Undenatured Type II Collagen (sometimes abbreviated UC-2 or native Type II collagen) is a…
Joint Health
UC-II® (Undenatured Type II Collagen — Lonza)
UC-II® is the patented branded form of undenatured Type II collagen developed by InterHeal…

Explore Other Ingredients

Joint Health
Chondroitin
Chondroitin, a key component of cartilage, is commonly supplemented as chondroitin sulfate…
Cognitive
Rhodiola Rosea
Rhodiola rosea is an adaptogenic herb traditionally used in cold northern regions to comba…
Cognitive
Suntheanine®
Suntheanine® is a patented, 100% pure L-isomer theanine produced via an enzymatic process…

Frequently asked questions about Flexigo™ (Devil's Claw Joint Health)

What is Flexigo?

Flexigo™ is a standardized Devil'S claw extract (Harpagophytum procumbens, also Harpagophytum zeyheri) from Southern Africa — developed by Nexira (France) as natural joint health solution.

What is Flexigo used for?

Flexigo is researched primarily for Joint Health. Multiple RCTs of Devil's Claw extracts (including Flexigo-grade) show pain reduction and improved mobility in osteoarthritis. systematic review confirmed efficacy. Effect comparable to non-pharmaceutical alternatives.

What is the recommended dosage of Flexigo?

The clinically studied dose is 1.8-3 g/day extract providing 50-100 mg harpagosides daily; varies by standardization Always follow the product label and check with a healthcare provider for personal advice.

Is Flexigo safe, and does it have side effects?

For most healthy adults, Flexigo is well tolerated at studied doses. Reported effects can include: Generally well-tolerated. GI distress (nausea, diarrhea) — most common. It may also interact with some medications. Flexigo is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Flexigo interact with any medications?

Possible interactions include: Anticoagulants — theoretical bleeding risk; modest at typical doses; consult. Diabetes medications — modest hypoglycemic effects; monitor. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Flexigo?

NutraSmarts rates the evidence for Flexigo as Moderate (3 out of 5). It is backed by 2 clinical trials and 5 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(5 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Wegener T, Lüpke NP. Treatment of patients with arthrosis of hip or knee with an aqueous extract of devil's claw (Harpagophytum procumbens DC.). Phytother Res. 2003;17(10):1165-1172. doi: 10.1002/ptr.1322.PubMedUsed to support: Clinical study (n=75) demonstrating that Harpagophytum procumbens extract significantly reduced pain and improved mobility in patients with hip and knee arthrosis; directly supports joint pain and mobility benefit claims for Flexigo™.
  2. Warnock M, McBean D, Suter A, Tan J, Whittaker P. Effectiveness and safety of Devil's Claw tablets in patients with general rheumatic disorders. Phytother Res. 2007;21(12):1228-1233. doi: 10.1002/ptr.2288.PubMedUsed to support: Open clinical study showing Devil's Claw tablets significantly reduced pain scores and improved functional status in patients with rheumatic disorders; supports anti-inflammatory and joint pain relief claims.
  3. Gagnier JJ, van Tulder M, Berman B, Bombardier C. Herbal medicine for low back pain. Cochrane Database Syst Rev. 2006;2006(2):CD004504. doi: 10.1002/14651858.CD004504.pub3.PubMedUsed to support: Cochrane systematic review concluding that Harpagophytum procumbens (Devil's Claw) provides moderate evidence for short-term improvement in low back pain; supports clinical and athletic application claims.
  4. Huang TH, Tran VH, Duke RK, Tan S, Chrubasik S, Roufogalis BD, Duke CC. Harpagoside suppresses lipopolysaccharide-induced iNOS and COX-2 expression through inhibition of NF-kappa B activation. J Ethnopharmacol. 2006;104(1-2):149-155. doi: 10.1016/j.jep.2005.08.055.PubMedUsed to support: Establishes the mechanism of action: harpagoside (the key standardized compound in Flexigo™) suppresses inflammatory enzymes iNOS and COX-2 via NF-κB inhibition; supports inflammation marker reduction claim.
  5. Grant L, McBean DE, Fyfe L, Warnock AM. A review of the biological and potential therapeutic actions of Harpagophytum procumbens. Phytother Res. 2007;21(3):199-209. doi: 10.1002/ptr.2029.PubMedUsed to support: Comprehensive review of clinical and pharmacological evidence for Devil's Claw in joint and musculoskeletal conditions; supports the breadth of evidence underlying Flexigo's therapeutic claims including EFSA-pending status.